SEC Company Response from Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) (TNXP) — May 14, 2018
Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)
Date: May 14, 2018 · CIK: 0001430306 · Accession: 0001615774-18-003727
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-224586
Letter
Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 306
New York, New York 10022
May 14, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Tonix Pharmaceuticals Holding Corp.
Registration Statement on Form S-3 (File No. 333-224586)
Filed on May 1, 2018
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 4:30 p.m., Eastern Standard Time, on May 16, 2018, or as soon as practicable thereafter.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.
[Signature page follows.]
Very truly yours,
TONIX PHARMACEUTICALS
Show Raw Text
CORRESP
1
filename1.htm
Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 306
New York, New York 10022
May 14, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Tonix Pharmaceuticals Holding Corp.
Registration Statement on Form S-3 (File No. 333-224586)
Filed on May 1, 2018
Ladies and Gentlemen:
In accordance with Rule
461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. (the “Company”) hereby
requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective
by the Securities and Exchange Commission (the “Commission”) at 4:30 p.m., Eastern Standard Time, on May 16,
2018, or as soon as practicable thereafter.
Please call Steven
M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any
questions.
[Signature page
follows.]
Very truly yours,
TONIX PHARMACEUTICALS
HOLDINGS CORP.
By: /s/ Bradley Saenger
Name: Bradley Saenger
Title: Chief Financial Officer